Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.

[1]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[2]  A. Ido,et al.  Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseases , 2017, Alimentary pharmacology & therapeutics.

[3]  D. D. de Jong,et al.  Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. , 2016, Journal of Crohn's & colitis.

[4]  L. Dieleman,et al.  Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study , 2016, Inflammatory bowel diseases.

[5]  N. Narula,et al.  Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease , 2016, Alimentary pharmacology & therapeutics.

[6]  Christopher McCabe,et al.  Cost Effectiveness Modelling for Health Technology Assessment , 2015 .

[7]  T. Connelly,et al.  Predictors of recurrence of Crohn's disease after ileocolectomy: a review. , 2014, World journal of gastroenterology.

[8]  Alka B. Patel,et al.  Postoperative Complications and Emergent Readmission in Children and Adults with Inflammatory Bowel Disease Who Undergo Intestinal Resection: A Population-based Study , 2014, Inflammatory bowel diseases.

[9]  G. Corazza,et al.  Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease , 2013, The European Journal of Health Economics.

[10]  J. Mate,et al.  Intensification of infliximab therapy in Crohn's disease: efficacy and safety. , 2012, Journal of Crohn's & colitis.

[11]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[12]  J. Gisbert,et al.  Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response , 2011, Journal of clinical gastroenterology.

[13]  W. Blonski,et al.  What is the optimal therapy for Crohn’s disease: step-up or top-down? , 2010, Expert review of gastroenterology & hepatology.

[14]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[15]  L. Peyrin-Biroulet,et al.  Early Crohn disease: a proposed definition for use in disease-modification trials , 2010, Gut.

[16]  S. Devlin,et al.  Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. , 2010, The Medical clinics of North America.

[17]  S. Ng,et al.  Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit , 2009, European journal of gastroenterology & hepatology.

[18]  C. Porter,et al.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. , 2008, Gastroenterology.

[19]  C. Fiocchi,et al.  Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. , 2008, Journal of Crohn's & colitis.

[20]  N. Hyman,et al.  Death after Bowel Resection: Patient Disease, Not Surgeon Error , 2008, Journal of Gastrointestinal Surgery.

[21]  M. Regueiro,et al.  Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.

[22]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[23]  C. Bernstein,et al.  Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.

[24]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  O Bernell,et al.  Risk factors for surgery and postoperative recurrence in Crohn's disease. , 2000, Annals of surgery.

[26]  B. Feagan,et al.  An Evaluation of Utility Measurement in Crohn's Disease , 1997, Inflammatory bowel diseases.

[27]  Guidelines for the Economic Evaluation of Health Technologies in Ireland 2014 , 2022 .